UNSPSC 51372901: Bezitramide

This classification denotes an analgesic agent with the molecular formula C31H32N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3KXW0Y310I, chemically known as 2-benzimidazolinone, 1-(1-(3-cyano-3,3-diphenylpropyl)-4-piperidyl)-3-propionyl- but generally known as bezitramide, which bears US NIH Compound Identifier 61791. European Medicines Agency schedules Bezitramide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05811MIG. The term BEZITRAMIDE is an International Non-Proprietary Name.

UNSPSC 51372901 Bezitramide is a Commodity code that nominally identifies a specific opioid pharmaceutical product; however, recent state and local solicitations tagged under this code reflect a much broader scope of pharmaceutical procurement, including naloxone (an opioid antagonist), over-the-counter products, and therapeutic pharmacy initiatives rather than bezitramide specifically. State and local issuing bodies soliciting under this code span county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. The work being bought includes annual procurement of naloxone and drug deactivation systems for community health support, establishment of direct-to-manufacturer prescription programs to improve fulfillment efficiency and cost management, and framework agreements for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers to state and local government facilities. Vendors must typically hold current Good Manufacturing Practices (cGMP) certification and Drug Supply Chain Security Act (DSCSA) compliance; maintain relationships with authorized pharmaceutical wholesalers; provide detailed product information including National Drug Codes, SKUs, and packaging configurations; and carry comprehensive liability and professional insurance coverage ranging from $2,000,000 to $5,000,000 per occurrence.

Recent activity spans Florida, Texas, Minnesota, and Oregon. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023, through a competitive bidding process with a two-year initial term and one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for establishing direct-to-manufacturer prescription programs serving self-insured state employee health plans. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by Minnesota's Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026, covering Oregon and multiple state and local facilities, with contract effectiveness July 1, 2026. Award timelines and dollar values are not disclosed in current solicitation materials.